Trials / Terminated
TerminatedNCT03580694
Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 Study of REGN4659 (Anti-CTLA-4 mAb) in Combination With Cemiplimab (Anti-PD-1 mAb) in the Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this trial is to study REGN4659 and cemiplimab in treatment-experienced, non-small cell lung cancer (NSCLC) patients. There are 2 phases of this study: a dose escalation phase and a dose expansion phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN4659 | REGN4659 will be administered by intravenous (IV) infusion. |
| DRUG | Cemiplimab | Cemiplimab will be administered by intravenous (IV) infusion. |
Timeline
- Start date
- 2018-06-27
- Primary completion
- 2019-12-04
- Completion
- 2019-12-04
- First posted
- 2018-07-09
- Last updated
- 2020-03-13
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03580694. Inclusion in this directory is not an endorsement.